International fund giants substantially increase their holdings of Hengrui Pharmaceuticals Sun Piaoyang personally denounces 316 million overweight new drug companies

In the past two days, when the 2020 financial report and the first quarter of 2021 are announced, Hengrui Medicine (600276) has made various moves
.

Regarding Hengrui Pharmaceuticals, combined with the latest financial reports, the industry has many interpretations: whether it is Hengrui who is deeply trapped in "slow growth, excessive valuation, difficulty in centralized procurement, sales turmoil.
.
.
", or "holding a big move "Hengrui, who is ready to go and still arrogant to the crowd", has disputes on all sides
.

In a lot of information, Sina Medicine noticed two of them, which seemed to have an unclear meaning:

1.
Boss blessing:

According to the first quarterly report of Hengrui Medicine, with the "national team" and Beijing capital choosing to lighten up Hengrui Medicine, Oppenheimer Fund increased its holdings by 16.
5706 million shares.
This is the first time it has increased its holdings since 2020.
Swiss Medicine
.

According to the data, Oppenheimer is one of the largest global asset management companies in the United States.
It has become an investment myth because of its precise operation of buying bottoms in A-shares and ushering in skyrocketing soaring, especially since it has been in Maotai for nearly four years.
, Hao earned billions of dollars, it is a battle to become a god
.

       In 2017, Hengrui's annual report showed that Oppenheimer entered Hengrui Medicine for the first time and became the top ten tradable stocks
.

       In 2018, Oppenheimer reduced its holdings in Hengrui Pharmaceuticals in the first quarter and the second quarter, and successfully missed a wave of decline in the market
.

       In 2018, the “black swan” of the pharmaceutical industry appeared frequently, and many public equity funds reduced their holdings of Hengrui Pharmaceuticals, but Oppenheimer Funds bucked the trend and increased their holdings by nearly 20 million shares
.

       At the beginning of 2019, Hengrui Pharmaceuticals started an 11-month rebound in the market, the stock price doubled, and the Oppenheimer Fund made huge profits
.

       In 2020, the Oppenheimer Fund perfectly avoided the falling market at the end of the fourth quarter, reducing its holdings of Hengrui by nearly 16 million shares in the second and third quarters, perfectly staggering the downward trend
.

       Today, in the first quarter of 2021, Hengrui Pharmaceuticals, which once had a market value of 600 billion yuan, has fallen by 17% overall, with a maximum amplitude of nearly 30%
.

       On this occasion, Oppenheimer Fund once again increased its position in Hengrui Medicine, which naturally caused a sensation
.

       However, it is worth mentioning that the Oppenheimer Fund has also stumbled on Dong Ejiao (000423).
After all, this time the Oppenheimer Fund once again bucked the trend and blessed Hengrui Medicine.
Can we continue to write the investment myth? Wait and see
.

       2.
Sun Piaoyang's new drug company

       On April 19, Hengrui Pharmaceuticals issued an announcement that Shanghai Hengrui and Sun Piaoyang will continue to increase their capital in Ruilidi to support their capital needs.
The two will increase their capital by 474 million yuan and 316 million yuan respectively
.

       In July 2020, Ruilidi was jointly established by Shanghai Hengrui with a contribution of 60 million yuan and Sun Piaoyang's personal contribution of 40 million yuan, responsible for the research and development, production, sales and related import and export business of antiviral therapy
.

       Many investors believe that Hengrui Pharmaceutical's active involvement in new areas will be a new bargaining chip for Hengrui Pharmaceuticals to stimulate the capital market and digest valuation bubbles.
It will not even rule out the possibility of a separate IPO in the future, opening up a new battlefield for the company
.

       However, some investors expressed concern that Hengrui Pharmaceuticals, as a leader in China's pharmaceutical industry, still adopts self-construction methods such as the establishment of Ruili Di to expand its scale.
This is completely different from the growth path of many major international pharmaceutical companies relying on mergers and acquisitions to achieve dominance.

.

       Reference source: China Fund News "Escaped Maotai! Oppenheimer makes another move: Contrary to the trend to increase holdings of Hengrui Medicine"